Viehbacher Christopher 4

What Happened Christopher Viehbacher, President, CEO and a director of Biogen (BIIB), was granted 38,015 restricted stock units (RSUs) on February 13, 2026. The grant is reported as a derivative acquisition at $0.00 per share (i.e., an award of RSUs rather than an open‑market purchase). This is a compensatory equity grant, not a sale or purchase of outstanding shares.

Key Details

• Transaction date: 2026-02-13; Form 4 filed: 2026-02-17 (Accession 0000875045-26-000035).
• Award: 38,015 restricted stock units (RSUs) recorded at $0.00 (derivative grant).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: RSUs vest in three equal yearly installments beginning on the first anniversary of the grant date (Feb 13, 2027).
• Timing: Filing appears timely (Form 4 filed within the usual reporting window); no late‑filing flag in the excerpt.

Context Restricted stock units are compensation awards that convert into actual shares only as they vest; they do not represent immediately tradable stock. Such grants are common executive compensation and should not be interpreted as a direct buy/sell signal by the insider. Any tax withholding or share surrender related to vesting was not disclosed in this filing.